The short answer
Retatrutide (LY3437943) is an investigational triple-receptor agonist peptide developed by Eli Lilly. It binds and activates the GIP, GLP-1, and glucagon receptors simultaneously, making it the first triple-agonist incretin currently progressing through the Phase 3 TRIUMPH clinical trial programme.
Key facts
- Chemical name
- LY3437943 (Retatrutide)
- Class
- Triple receptor agonist (GIP/GLP-1/Glucagon)
- Molecular weight
- ~4,731 Da
- Developer
- Eli Lilly and Company
- Status
- Investigational, pivotal Phase 3 reported
- Approval
- Not approved by FDA, EMA, or MHRA
- TRIUMPH-1
- 28.3% mean reduction at 80 wks (May 2026)
What is retatrutide chemically?
Retatrutide is a 39-amino-acid synthetic peptide analogue derived from the GIP scaffold, engineered with fatty-acid conjugation to extend its plasma half-life. It is a single-molecule triple agonist: one peptide chain that binds three distinct incretin family receptors at physiologically relevant concentrations.
Who developed retatrutide?
Retatrutide is being developed by Eli Lilly and Company under the internal code LY3437943. The programme sits alongside Lilly's earlier incretin work on dulaglutide (Trulicity) and tirzepatide (Mounjaro / Zepbound), and represents the next generation beyond dual GIP/GLP-1 agonism.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What is its regulatory status?
Retatrutide is an investigational compound. It has not received marketing authorisation from the FDA, EMA or MHRA and is available only within clinical-trial and research settings. The pivotal Phase 3 trials have now reported (TRIUMPH-1 in May 2026, TRIUMPH-2 and -3 in July 2026), and Eli Lilly has signalled an intended FDA filing in the first quarter of 2027.
Why is it studied?
Phase 2 data in the New England Journal of Medicine (Jastreboff et al., 2023) reported the largest weight reductions then observed for any single-molecule incretin agonist. The Phase 3 programme has since reinforced that position: TRIUMPH-1 reported mean reduction of 28.3% at 80 weeks on its highest dose arm. This has made retatrutide one of the most widely referenced compounds in current metabolic pharmacology literature.
Frequently asked questions
Is retatrutide the same as tirzepatide?
No. Tirzepatide is a dual GIP/GLP-1 agonist; retatrutide adds glucagon-receptor activity, making it a triple agonist.
Is retatrutide approved anywhere?
No. Retatrutide has not been approved by any regulator worldwide and remains investigational, despite the pivotal Phase 3 trials having reported positively during 2026.
What does LY3437943 mean?
It is Eli Lilly's internal development code for retatrutide, used in trial registrations and published research.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- RefJastreboff et al., NEJM 2023nejm.org
- RefTRIUMPH-1 topline results: Eli Lillyinvestor.lilly.com
- PubChemPubChem: Retatrutidepubchem.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · TRIUMPH-1 (NCT05929066). Retatrutide Phase 3 obesity trialclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-2 (NCT05929079). Retatrutide in type 2 diabetesclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-3 (NCT05882045). Retatrutide + established CVDclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-4 (NCT05931367). Retatrutide once weeklyclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-5 (NCT06662383). Retatrutide vs tirzepatideclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-6 (NCT06859268). Maintenance of weight reductionclinicaltrials.gov
- PubMedJastreboff AM et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity. NEJM 2023 (PMID 37366315)pubmed.ncbi.nlm.nih.gov
- PubMedRosenstock J et al., Retatrutide for people with type 2 diabetes. Lancet 2023 (PMID 37385280)pubmed.ncbi.nlm.nih.gov
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More Retatrutide Research articles
- Retatrutide Structure and Sequence39 residues on a modified GIP scaffold with a C20 diacid at Lys17. Why the backbone is GIP rather than GLP-1, and what the lipid is for.
- What Does "Reta" Mean?Reta is informal shorthand for retatrutide. What the full name encodes under WHO INN conventions, and why the -tide suffix matters.
- What "Reta" on a Label Actually Tells YouAn informal term for material sold as retatrutide for laboratory research. What the name does and does not tell you about the contents.
- Retatrutide vs Mounjaro, Ozempic and WegovyMounjaro is tirzepatide, Ozempic is semaglutide, and retatrutide is neither. One, two and three receptors - and why the headline figures rarely compare.
- Is Retatrutide FDA Approved? Regulatory Status ExplainedRetatrutide is not FDA approved. It is an investigational peptide in the Phase 3 TRIUMPH programme. Current EMA, MHRA and FDA regulatory status explained.